dc.contributor.author | Demetriou, Victoria L. | en |
dc.contributor.author | van de Vijver, D. A. M. C. | en |
dc.contributor.author | Kousiappa, Ioanna | en |
dc.contributor.author | Balotta, Claudia | en |
dc.contributor.author | Clotet, B. | en |
dc.contributor.author | Grossman, Z. | en |
dc.contributor.author | Jørgensen, L. B. | en |
dc.contributor.author | Lepej, S. Z. | en |
dc.contributor.author | Levy, I. | en |
dc.contributor.author | Nielsen, C. | en |
dc.contributor.author | Paraskevis, Dimitrios N. | en |
dc.contributor.author | Poljak, M. | en |
dc.contributor.author | Roman, F. | en |
dc.contributor.author | Ruiz, L. | en |
dc.contributor.author | Schmidt, J. -C | en |
dc.contributor.author | Vandamme, A. -M | en |
dc.contributor.author | van Laethem, K. V. | en |
dc.contributor.author | Vercauteren, J. | en |
dc.contributor.author | Kostrikis, Leontios G. | en |
dc.creator | Demetriou, Victoria L. | en |
dc.creator | van de Vijver, D. A. M. C. | en |
dc.creator | Kousiappa, Ioanna | en |
dc.creator | Balotta, Claudia | en |
dc.creator | Clotet, B. | en |
dc.creator | Grossman, Z. | en |
dc.creator | Jørgensen, L. B. | en |
dc.creator | Lepej, S. Z. | en |
dc.creator | Levy, I. | en |
dc.creator | Nielsen, C. | en |
dc.creator | Paraskevis, Dimitrios N. | en |
dc.creator | Poljak, M. | en |
dc.creator | Roman, F. | en |
dc.creator | Ruiz, L. | en |
dc.creator | Schmidt, J. -C | en |
dc.creator | Vandamme, A. -M | en |
dc.creator | van Laethem, K. V. | en |
dc.creator | Vercauteren, J. | en |
dc.creator | Kostrikis, Leontios G. | en |
dc.date.accessioned | 2019-11-04T12:50:31Z | |
dc.date.available | 2019-11-04T12:50:31Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53051 | |
dc.description.abstract | Background HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) have a predictive value for disease progression, independently of CD4 counts and plasma viral load. Methodology/Principal Findings Molecular-beacon-based real-time PCR was used to measure HIV-1 second template switch (STS) DNA in PBMC in newly-diagnosed HIV-1 patients across Europe. These patients were representative for the HIV-1 epidemic in the participating countries and were carrying either drug-resistant or sensitive viral strains. The assay design was improved from a previous version to specifically detect M-group HIV-1 and human CCR5 alleles. The findings resulted in a median of 3.32 log10 HIV-1 copies/106 PBMC and demonstrated for the first time no correlation between cellular HIV-1 DNA load and transmitted drug-resistance. A weak association between cellular HIV-1 DNA levels with plasma viral RNA load and CD4+ T-cell counts was also reconfirmed. Co-receptor tropism for 91% of samples, whether or not they conferred resistance, was CCR5. A comparison of pol sequences derived from RNA and DNA, resulted in a high similarity between the two. Conclusions/Significance An improved molecular-beacon-based real-time PCR assay is reported for the measurement of HIV-1 DNA in PBMC and has investigated the association between cellular HIV-1 DNA levels and transmitted resistance to antiretroviral therapy in newly-diagnosed patients from across Europe. The findings show no correlation between these two parameters, suggesting that transmitted resistance does not impact disease progression in HIV-1 infected individuals. The CCR5 co-receptor tropism predominance implies that both resistant and non-resistant strains behave similarly in early infection. Furthermore, a correlation found between RNA- and DNA-derived sequences in the pol region suggests that genotypic drug-resistance testing could be carried out on either template. © 2010 Demetriou et al. | en |
dc.source | PLoS ONE | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956214553&doi=10.1371%2fjournal.pone.0010976&partnerID=40&md5=469bd07ab64f4249b0d10808f5992b6d | |
dc.subject | Europe | en |
dc.subject | article | en |
dc.subject | human | en |
dc.subject | Humans | en |
dc.subject | adult | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | major clinical study | en |
dc.subject | quantitative analysis | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | male | en |
dc.subject | allele | en |
dc.subject | genotype | en |
dc.subject | HIV Infections | en |
dc.subject | human cell | en |
dc.subject | genetics | en |
dc.subject | virus load | en |
dc.subject | virus RNA | en |
dc.subject | Alleles | en |
dc.subject | Base Sequence | en |
dc.subject | DNA Primers | en |
dc.subject | polymerase chain reaction | en |
dc.subject | virology | en |
dc.subject | Viral Load | en |
dc.subject | Human immunodeficiency virus 1 | en |
dc.subject | HIV-1 | en |
dc.subject | CD4 lymphocyte count | en |
dc.subject | nucleotide sequence | en |
dc.subject | antiviral resistance | en |
dc.subject | Human immunodeficiency virus 1 infection | en |
dc.subject | proteinase inhibitor | en |
dc.subject | nonnucleoside reverse transcriptase inhibitor | en |
dc.subject | virus DNA | en |
dc.subject | real time polymerase chain reaction | en |
dc.subject | primer DNA | en |
dc.subject | chemokine receptor CXCR4 | en |
dc.subject | virus genome | en |
dc.subject | sequence homology | en |
dc.subject | DNA, Viral | en |
dc.subject | Drug Resistance, Viral | en |
dc.subject | molecular beacon | en |
dc.subject | peripheral blood mononuclear cell | en |
dc.subject | chemokine receptor CCR5 | en |
dc.subject | Receptors, CCR5 | en |
dc.subject | Sequence Homology, Nucleic Acid | en |
dc.subject | double stranded DNA | en |
dc.subject | genomic DNA | en |
dc.subject | long terminal repeat | en |
dc.subject | Pol protein | en |
dc.subject | viral tropism | en |
dc.title | Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1371/journal.pone.0010976 | |
dc.description.volume | 5 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Cited By :7</p> | en |
dc.source.abbreviation | PLoS ONE | en |
dc.contributor.orcid | Kostrikis, Leontios G. [0000-0002-5340-7109] | |
dc.contributor.orcid | Paraskevis, Dimitrios [0000-0001-6167-7152] | |
dc.gnosis.orcid | 0000-0002-5340-7109 | |
dc.gnosis.orcid | 0000-0001-6167-7152 | |